A research team led by Marcos Vilas Boas Filho and Valber de Albuquerque Pedrosa at São Paulo State University (UNESP) in Botucatu, Brazil, working with colleagues at the same institution, has now demonstrated a compact alternative: an electrochemical immunosensor built on a bioconjugated gold electrode that can generate melatonin-associated signals directly in homogenized kidney, liver, and heart tissue from laboratory rats. Published in Discover Electrochemistry, the study is billed as the first proof-of-concept demonstration of electrochemical immunosensing for melatonin in extrapineal tissue. Rather than seeking the lowest detection limit in the field, the team set out to show that antibody-based molecular recognition could be married to electrochemical transduction in matrices as chemically hostile as tissue homogenates.

The analytical chemistry underlying conventional melatonin measurement is well established. Techniques such as chemiluminescence, fluorometry, ultraviolet–visible spectrophotometry, gas chromatography–mass spectrometry, and high-performance liquid chromatography all deliver robust performance, but they demand multiple instrumental platforms, labor-intensive preparation, and long analysis times. Melatonin’s intrinsic photoreactivity compounds the difficulty, requiring manipulation under light-restricted conditions to prevent degradation. Electrochemical biosensors have emerged as attractive alternatives because of their low detection limits, operational simplicity, and rapid response, and recent years have seen nanostructured platforms achieve impressively low limits of detection in serum, urine, food, and pharmaceutical samples. A paper-based graphite electrode, a molecularly imprinted polymer platform, and a sensor incorporating core–shell Cu@Pt nanoparticles have all reported submicromolar detection. But nearly all of these rely on the direct electrochemical oxidation of melatonin, an approach vulnerable to electrode fouling, matrix interference, and overlapping signals from other electroactive compounds—and none had been applied to extrapineal tissue.

The Brazilian team’s strategy inverts that logic. Instead of oxidizing melatonin directly, they built an indirect sensing architecture in which the hormone is captured by an immobilized antibody, and its presence is read out as a measurable suppression of a redox probe’s current. The fabrication begins with a gold electrode 1.7 millimeters in diameter, onto which a self-assembled monolayer of 11-mercaptoundecanoic acid is formed by gold–sulfur bonding, exposing terminal carboxyl groups. These groups are then activated with the classic EDC/NHS coupling chemistry, generating reactive NHS-esters that covalently link to free amine groups on a polyclonal anti-melatonin antibody during overnight incubation at 4 degrees Celsius. The result is the Au/SAM-MUA/anti-ME interface: a stable, antibody-decorated surface in which every subsequent molecular event translates into an electrical signature.

Characterization of the assembly followed the standard toolbox of electroanalytical science. Cyclic voltammetry using the ferricyanide/ferrocyanide couple as a redox probe showed a progressive decline in peak current as each layer was added, confirming that the growing protein and organic films were hindering electron transfer as designed. Electrochemical impedance spectroscopy told the same story quantitatively: the charge-transfer resistance of the bare gold electrode stood at just 5 kilo-ohms, rising to 13 kilo-ohms after monolayer formation, 29 kilo-ohms after EDC/NHS activation, 30 kilo-ohms after antibody immobilization, and a marked 40 kilo-ohms once melatonin bound to the antibody layer. That final jump, the team notes, is the analytical heart of the device—each melatonin molecule captured at the surface adds insulating mass, physically blocking diffusion of the redox probe and deepening the measurable signal.

With square-wave voltammetry optimized at a frequency of 100 hertz, a step potential of 5 millivolts, and a pulse amplitude of 20 millivolts, the researchers calibrated the sensor against commercial melatonin standards across a linear range of 20 to 120 micromolar. The calibration curve carried a negative slope of –0.0034, exactly what the suppression mechanism predicts: the blank current of 0.59 microamperes fell to 0.18 microamperes at 120 micromolar melatonin. The derived figures of merit were a limit of detection of approximately 4 micromolar, a limit of quantification of 14 micromolar, and a striking electrochemical sensitivity of 250 microamperes per micromolar per square centimeter—among the highest sensitivities reported for any electrochemical melatonin platform, and the second highest overall. Recovery analysis with spiked samples reached 99.8 percent, and the sensor held 96.3 percent of its signal between consecutive measurement days, retaining functional integrity for up to eight days before the biological layer required re-immobilization.

Selectivity testing against common biological interferents revealed both strengths and honest limits. Serotonin, dopamine, and uric acid each shifted the redox signal by only 0.8 to 4.0 percent, well within acceptable tolerances. But ascorbic acid alone produced a 9.5 percent suppression, and a mixture of all interferents together caused an 11 percent deviation—statistically significant and a reminder that nonspecific matrix effects can creep into any antibody-based measurement in complex fluids. The authors attribute this partly to possible conformational changes in the antibody at certain pH values, which may partially expose the underlying electrode surface to blocking by other molecules. They are careful to frame the sensor’s selectivity as demonstrable but not yet definitive under all biological conditions.

The biological application was where the platform earned its novelty claim. Thirty male Wistar rats were divided into a treated group receiving intraperitoneal melatonin at 25 milligrams per kilogram three times weekly for four weeks, and a control group receiving saline. Liver, heart, and kidney samples were harvested, homogenized, and spiked with a known melatonin standard before analysis. Across all three tissues, successive additions of homogenate produced the characteristic progressive suppression of the ferri/ferrocyanide anodic current, and tissues from melatonin-treated animals consistently generated stronger current suppression than control samples. Kidney homogenates produced the greatest effect, followed by heart and liver—a pattern the researchers note aligns with known physiology, since the kidney is central to eliminating melatonin metabolites, the liver metabolizes the hormone via cytochrome P450 enzymes, and cardiac tissue harbors extrapineal melatonin and receptors tied to cardiovascular regulation.

The team is appropriately measured about what the tissue data mean. Because the current-response plots in the homogenates lacked sufficient linearity to derive formal detection limits for those matrices, and because no direct comparison with HPLC or LC–MS/MS was performed, the tissue signals are presented strictly as preliminary, qualitative proof-of-concept responses rather than precise quantifications. Still, the implications are considerable. The work establishes, for the first time, that an antibody-functionalized electrochemical interface can register melatonin-associated differences in kidney, liver, and heart tissue—opening a path toward rapid, point-of-care monitoring of hormone distribution in contexts where chromatography is impractical. The researchers say future work will focus on validating the platform against established chromatographic methods and implementing matrix-matched calibration to sharpen quantitative accuracy, potentially extending the technology to studies of circadian biology, neurodegenerative disease research, and antioxidant therapy monitoring where melatonin’s reach beyond the brain matters most.

The choice of an indirect immunosensing format carries practical implications worth underscoring. Because melatonin itself is not oxidized at the electrode surface, the many electroactive species that populate tissue homogenates—ascorbate, urate, catecholamines—compete far less directly for the analytical signal. The trade-off is kinetic and structural: antibody–antigen binding is slower than a simple electron-transfer event, and the biological recognition layer is inherently fragile, which is why the team found the interface required re-immobilization after roughly eight days of use. Such operational lifetimes are typical of protein-based sensors and represent a genuine engineering constraint for any future field deployment.

The tissue-specific response pattern observed in the rat study also merits interpretation. The strongest suppression in kidney homogenates is consistent with the organ’s role as the principal route of melatonin metabolite excretion, while the hepatic signal reflects cytochrome P450-mediated metabolism, the dominant catabolic pathway for the hormone in mammals. Cardiac tissue, meanwhile, is of particular interest because melatonin receptors expressed in myocardium have been linked to blood pressure regulation and cardioprotection, making a rapid tissue-level assay potentially valuable in cardiovascular research.

Methodologically, the spiking approach used in the proof-of-concept experiments deserves note. By adding a known commercial melatonin standard to each homogenate, the researchers could verify that the antibody layer remained functional even amid the proteins, lipids, and salts of a crude tissue matrix. The absence of a chromatographic cross-check, however, means the absolute endogenous concentrations in treated versus control animals remain unknown. Establishing that correlation, alongside matrix-matched calibration curves, will be the decisive next step in determining whether this bioconjugated gold interface can evolve from a qualitative indicator of melatonin-associated tissue responses into a genuinely quantitative analytical instrument for circadian and biomedical research.

Subject of Research: Development of a bioconjugated gold electrochemical immunosensor for detecting melatonin in extrapineal rat tissues

Article Title: Electrochemical melatonin detection in extrapineal tissue using a bioconjugated sensor

Article References: Filho, M. V. B., Agneis, M. L. G., de Souza, M. C., Gavioli, V. D., de Castro, G. R., Seiva, F. R. F., de Almeida Chuffa, L. G., & de Albuquerque Pedrosa, V. (2026). Electrochemical melatonin detection in extrapineal tissue using a bioconjugated sensor. Discover Electrochemistry, 3(1), Article 75. https://doi.org/10.1007/s44373-026-00162-x

Image Credits: AI Generated

DOI: 10.1007/s44373-026-00162-x

Keywords: melatonin, immunosensor, electrochemistry, biosensor, gold electrode, extrapineal tissue, square-wave voltammetry, electrochemical impedance spectroscopy, Wistar rats, circadian rhythm, antioxidant, tissue homogenate

The circadian clock is an intrinsic timekeeping system that regulates physiological and behavioral processes in mammals. At its core, the clock machinery comprises transcriptional-translational feedback loops involving clock proteins such as CLOCK, BMAL1, and cryptochrome (CRY). The orchestrated expression of these genes and proteins leads to rhythmic physiological outputs, precisely regulating sleep-wake cycles, hormone production, metabolism, and other essential functions in a 24-hour period. Understanding how to manipulate this timing mechanism has remained a major scientific and therapeutic challenge due to the intricacies of clock regulation and its tissue-wide synchrony.

Mic-628 targets the repressor protein CRY1, binding in a way that promotes the assembly of a unique molecular complex with CLOCK and BMAL1, along with CRY1 and itself. This quaternary complex acts specifically on a tandem “dual E-box” element within the Per1 gene promoter, selectively enhancing Per1 transcription. Unlike other interventions that broadly affect circadian genes, Mic-628’s mechanism results in a precise, unidirectional advance of Per1 expression, a critical driver of clock phase resetting. This selective activation paves the way for controlled phase advancement of the circadian rhythm, potentially alleviating circadian misalignment disorders.

Remarkably, Mic-628 induces phase advancements in both the central clock located in the brain’s suprachiasmatic nucleus (SCN) and peripheral clocks found in various tissues such as the lungs. Traditionally, peripheral clocks and the central pacemaker function semi-independently, and external cues often have disparate effects on these clocks. The study shows that Mic-628 advances these clocks synchronously, regardless of the dosing time, highlighting the compound’s robust and consistent efficacy. This synchronous phase adjustment suggests a systemic modulation of the circadian machinery through a shared molecular pathway targeted by Mic-628.

The team tested Mic-628 in an established mouse model simulating jet lag through a 6-hour advance of the light-dark cycle, mimicking eastward transmeridian travel—a major source of circadian disruption for humans. Here, a single oral dose of Mic-628 remarkably reduced the re-entrainment period from seven days to four. This accelerated adaptation demonstrates the drug’s potent effect in rapidly aligning the internal clock with the external environment. Such findings have significant translational potential for developing therapeutic interventions that reduce the debilitating impacts of jet lag on performance, cognition, and overall health.

Underlying the mechanism of Mic-628’s action is a negative auto-regulatory feedback loop mediated by the PER1 protein. This feedback loop ensures the stability of phase advancement by incorporating self-regulatory properties of the Per1 gene product itself. Mathematical modeling conducted alongside experimental studies confirmed that this feedback imposes a stable and unidirectional effect on circadian phase shifts, avoiding unstable or oscillatory adjustments. Such molecular and computational insights give credence to the compound’s capacity as a “smart drug,” capable of fine-tuning circadian rhythms within biologically manageable bounds.

Circadian misalignment is a broadly impactful social and medical issue. Eastward travel, night-shift work, and irregular sleep schedules require phase advancing the biological clock, a process that is inherently slower and more prone to maladaptive effects than phase delay. Conventional methods such as timed exposure to bright light or administration of melatonin suffer from narrow therapeutic windows and inconsistent efficacy often dependent on precise timing. Mic-628 strikes a pivotal advancement by imparting consistent phase advancements regardless of administration timing, highlighting its potential to overcome existing pharmacological limitations.

The pharmacological breakthrough represented by Mic-628 lies not merely in its efficacy but in its specific targeting of molecular components within the circadian framework. By focusing on the repressor CRY1 and exploiting a dual E-box DNA element, the drug exemplifies a precision medicine approach designed from a mechanistic understanding of clock gene regulation. Such specificity limits off-target effects and maximizes the potential for clinical application with minimal adverse consequences, distinguishing Mic-628 from broad-spectrum chronobiotics.

Looking ahead, the researchers are committed to comprehensive evaluations of Mic-628’s safety and efficacy via continued preclinical trials and eventual human studies. The detailed elucidation of its molecular mechanism provides a strong foundation for rational drug development and clinical translation. If successful, Mic-628 could become the prototype for a new class of chronotherapeutics aimed at managing circadian rhythm disorders, ranging from jet lag and shift work maladaptation to more complex conditions involving circadian dysfunction.

This research is anticipated to be published in the prestigious Proceedings of the National Academy of Sciences (PNAS) in early 2026, contributing significant advancements to the fields of chronobiology and pharmacology. It reflects the collaborative effort of interdisciplinary scientists integrating molecular biology, neuroscience, genetics, and computational modeling—showcasing the power of cross-institutional teamwork in tackling intricate biological problems.

The discovery of Mic-628 also holds promise for broader implications beyond jet lag and shift work. Chronic circadian misalignment has been implicated in various health conditions, including metabolic syndrome, cardiovascular disease, mood disorders, and cancer progression. By providing a targeted tool to reset and stabilize circadian timing, Mic-628 could be pivotal in novel therapeutic strategies addressing these illnesses. Such translational potential underscores the importance of circadian biology in preventive medicine and long-term health management.

In summary, the development of Mic-628 represents a paradigm shift in circadian rhythm pharmacology. It leverages intricate molecular interactions within the core clock machinery to safely and effectively advance the circadian phase. Its ability to induce synchronized phase advances in central and peripheral clocks, independent of dosing time, marks a significant step toward practical clinical interventions for circadian misalignment disorders. This drug candidate brings new hope to millions affected by jet lag, shift work challenges, and other disruptions of their internal biological clocks.

Subject of Research: Circadian rhythm regulation and pharmacological phase advancement through selective Per1 induction by Mic-628.

Article Title: A Period1 inducer specifically advances circadian clock in mice.

News Publication Date: 23-Jan-2026.

Web References: DOI: 10.1073/pnas.2509943123.

Image Credits: Kanazawa University.

Keywords: Physiology, Genetics, Neuroscience, Molecular biology, Modeling, Pharmacology.

The ATP-binding cassette (ABC) transporters represent a large family of proteins responsible for translocating various substrates across cellular membranes utilizing ATP hydrolysis. Abcc5/MRP5, expressed abundantly in neural tissue, had long been hypothesized to contribute primarily to the efflux of organic anions and nucleoside analogues. However, the recent data suggest that its functional repertoire extends into realms crucial for neuronal communication and plasticity. This paradigm shift underscores the interconnectedness of membrane transport mechanisms with synaptic physiology and behavioral outputs.

Central to the study’s narrative is memory consolidation, the fundamental process by which transient experiences are forged into long-lasting memories. Through a combination of genetic, electrophysiological, and behavioral assays performed on murine models deficient in Abcc5, the research team demonstrated clear impairments in both short- and long-term memory paradigms. Intriguingly, these deficits correlated not only with altered neurotransmitter dynamics but also with disruption in gene expression patterns associated with synaptic remodeling. This implicates Abcc5 as a critical integrator of signaling events necessary for the stabilization of memory engrams.

Circadian rhythms, the endogenous oscillations governing physiological and behavioral cycles, are finely tuned by a network of molecular clocks and environmental cues. The study uncovered a hitherto unrecognized role for Abcc5 in the regulation of these rhythms. Mice bearing targeted deletions of Abcc5 exhibited aberrant locomotor activity patterns, desynchronization of core clock gene expression in the suprachiasmatic nucleus, and altered melatonin secretion profiles. These findings highlight that beyond its transporter function, Abcc5 may modulate circadian homeostasis by influencing signaling pathways linked to neuronal excitability and rhythmic gene transcription.

Glutamatergic neurotransmission, mediated primarily by the excitatory neurotransmitter glutamate, forms the backbone of synaptic communication in the central nervous system. Banks and colleagues provided compelling evidence that Abcc5 regulates aspects of glutamate signaling, notably through its impact on glutamate receptor trafficking and synaptic vesicle cycling. Electrophysiological recordings revealed diminished excitatory postsynaptic potentials and impaired long-term potentiation (LTP) in hippocampal slices derived from Abcc5 knockout animals. These functional impairments dovetail with the cognitive deficits observed in vivo, reinforcing the transporter’s role in sustaining synaptic plasticity.

Delving into the molecular underpinnings, the researchers employed advanced proteomic analyses and identified disrupted clustering of NMDA and AMPA receptor subunits in the absence of Abcc5. Such alterations compromise synaptic strength and adaptability, integral components of memory encoding processes. Moreover, the team observed altered levels of intracellular signaling molecules such as CaMKII and CREB, which are well-established mediators of activity-dependent gene expression pertinent to learning and memory.

The link between Abcc5 function and circadian signaling was further explored through transcriptomic profiling, which revealed misexpression of clock genes including Per1, Cry1, and Bmal1. These deviations suggest that Abcc5 might be necessary for the precise temporal control of gene expression cycles that orchestrate physiological rhythms. Additionally, altered redox states and ATP availability observed in mutant mice point towards a metabolic dimension to Abcc5’s regulatory role, integrating energy dynamics with circadian biochemical cascades.

Of particular significance is the potential translational implication of these findings. Disruptions in memory consolidation and circadian dysregulation are hallmark features of numerous neuropsychiatric conditions such as Alzheimer’s disease, schizophrenia, and mood disorders. By identifying Abcc5 as a nodal point connecting these processes, the study beckons the development of pharmacological modulators aimed at optimizing transporter activity. Such interventions could restore synaptic efficacy and stabilize biological rhythms, offering multifactorial remediation for cognitive and affective symptoms.

The research also opens exciting avenues for the study of drug resistance phenomena in psychiatric treatment. Given that ABC transporters are known to influence the pharmacokinetics of many neuroactive compounds, Abcc5 might serve as a bridge linking membrane transporter function with therapeutic outcomes. Understanding this relationship could refine dosing protocols and improve the efficacy of existing medications targeting glutamatergic pathways or circadian regulators.

Methodologically, the study’s strength lies in its integrative approach, combining in vivo behavioral assessments with exhaustive molecular characterizations. Techniques such as in situ hybridization, high-resolution microscopy, and patch-clamp electrophysiology provided a comprehensive picture of how genetic ablation of Abcc5 culminates in altered neuronal circuits and behavioral phenotypes. This multi-tiered strategy established causal links rather than mere associations, strengthening the validity of the conclusions drawn.

Furthermore, the work contributes novel insights into the intracellular trafficking roles played by ABC transporters in neurons, a comparatively underexplored aspect of their function. The authors propose a model whereby Abcc5 participates in the recycling and surface expression of key synaptic proteins, potentially influencing receptor availability and synaptic strength. This mechanistic framework invites broader examination across other members of the ABC transporter family and their involvement in neural dynamics.

Notably, the discoveries elucidate how peripheral and central functions of transporters such as Abcc5 are intertwined. While traditionally associated with xenobiotic clearance and cellular protection, this study places Abcc5 squarely in the domain of neurophysiology, underscoring the protein’s dualistic nature. Understanding these diverse roles will be critical as the field moves toward precision medicine approaches in neurology and psychiatry.

The implications for circadian biology are equally profound. As global lifestyles increasingly encroach upon natural rhythms, understanding molecular players like Abcc5 that govern the internal clock becomes ever more pressing. The transporter’s influence on rhythmic gene expression and behavioral patterns suggests it might also mediate the impact of environmental stressors on circadian stability, providing a molecular target for interventions aimed at circadian misalignment.

In conclusion, the work by Banks et al. presents a compelling narrative that redefines the functional landscape of the Abcc5 ATP-binding cassette transporter within the mammalian brain. By bridging the realms of memory, circadian biology, and synaptic signaling, these findings propel Abcc5 from a peripheral actor to a central orchestrator of neural health and behavior. Future research focused on this transporter could unveil transformative strategies to combat cognitive decline and circadian disturbances associated with neuropsychiatric illnesses, heralding a new era in brain therapeutics.

Subject of Research: The role of the murine ATP-binding cassette transporter C5 (Abcc5/MRP5/cMOAT) in memory consolidation, circadian rhythm regulation, and glutamatergic signaling.

Article Title: The murine ATP-binding cassette transporter C5 (Abcc5/MRP5/cMOAT) plays a role in memory consolidation, circadian rhythm regulation and glutamatergic signalling.

Article References: Banks, G., Cyranka, M., Vedovato, N. et al. The murine ATP-binding cassette transporter C5 (Abcc5/MRP5/cMOAT) plays a role in memory consolidation, circadian rhythm regulation and glutamatergic signalling. Transl Psychiatry 15, 218 (2025). https://doi.org/10.1038/s41398-025-03438-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03438-9